Items where authors include "Malik, Z."

Article

Rescigno, P., Porta, N., Finneran, L. et al. (26 more authors) (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205. 114103. ISSN 0959-8049

Goodyear, C.S., Patel, A., Barnes, E. et al. (118 more authors) (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6 (6). e339-e351. ISSN 2665-9913

Goodyear, C.S., Patel, A., Barnes, E. et al. (119 more authors) (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6 (6). e339-e351. ISSN 2665-9913

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534